argatroban

serpin family C member 1 ; Homo sapiens







34 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34381261 Cost-effectiveness of Argatroban Versus Heparin Anticoagulation in Adult Extracorporeal Membrane Oxygenation Patients. 2021 Aug 1
2 31894660 Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. 2020 Jan 1
3 33390937 Anticoagulation Resumption in a Patient With Mechanical Heart Valves, Antithrombin Deficiency, and Hemorrhagic Transformation Following Thrombectomy After Ischemic Stroke. 2020 1
4 25594496 Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis. 2015 Feb 2
5 23329795 Emerging applications of argatroban in the management of systemic malignancies: potential benefits besides its primary role as an antithrombin agent. 2013 Jan 18 1
6 18560242 Argatroban anticoagulation in renal dysfunction: a literature analysis. 2008 3
7 16293985 Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban. 2005 2
8 14759471 Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. 2004 Feb 1
9 15162900 Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature. 2004 May 1
10 15171962 Small-molecule direct antithrombins: argatroban. 2004 Mar 3
11 12627673 Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. 2003 Feb 1
12 12096932 Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? 2002 1
13 12361208 Direct antithrombin agents ameliorate disseminated intravascular coagulation in suspected heparin-induced thrombocytopenia thrombosis syndrome. 2002 Jul 2
14 12811008 Development of argatroban as an anticoagulant and antithrombin agent in Japan. 2002 2
15 12811013 Practical issues in the development of argatroban: a perspective. 2002 5
16 10822073 Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters. 2000 May 15 1
17 11011802 An update on heparins at the beginning of the new millennium. 2000 1
18 11065253 Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease. 2000 Nov 1
19 10226408 Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. 1999 Mar 1
20 10688418 Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. 1999 Sep 1
21 10726029 Heparin-induced thrombocytopenia: historical review. 1999 Oct 1
22 10726036 Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. 1999 Oct 1
23 9288875 Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. 1997 Sep 1
24 9469623 Development of argatroban, a direct thrombin inhibitor, and its clinical application. 1997 2
25 9469625 Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. 1997 1
26 8741550 [Traumatic thoracic aortic rupture--diagnosis and surgical repair]. 1996 Jul 1
27 8752690 [Familial Binswanger-type encephalopathy with Sneddon syndrome]. 1996 Feb 1
28 8776531 Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. 1996 Jun 1
29 9013237 [A case of Fournier's gangrene with healing accelerated by argatroban]. 1996 Dec 1
30 9528269 Clinical evaluation of the efficacy of an antithrombin agent "Argatroban" combined with exercise therapy on increase of the skeletal muscle blood flow. 1996 Jul 1 1
31 7518511 Characterization of platelet activity in neuroblastoma. 1994 May 1
32 1920862 [Thrombin.antithrombin III complex]. 1991 Jul 2
33 2264021 Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III. 1990 Sep 15 2
34 2686903 Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis. 1989 1